Why the study?
Does ivabradine improve symptoms and heart rate in a patient with COVID-19-induced postural orthostatic tachycardia syndrome?
Does ivabradine improve symptoms and heart rate in a patient with COVID-19-induced postural orthostatic tachycardia syndrome?
Ivabradine may be an effective pharmacological option for managing COVID-19-induced postural orthostatic tachycardia syndrome when non-pharmacological interventions fail.
May support ivabradine in refractory COVID-19 POTS; hypothesis-generating pending controlled trials.
A 22-year-old woman was referred with exertional dyspnoea and chest tightness 3 weeks following a diagnosis of COVID-19. Evaluation revealed a resting sinus tachycardia and criteria for postural orthostatic tachycardia syndrome were met. After non-pharmacological interventions failed to yield symptomatic improvement, ivabradine was commenced. This intervention was followed by a substantial improvement in the patient's exercise tolerance and energy levels and an objective reduction in supine and standing heart rate.
No takes yet. Share an insight, caveat, or question.
O'Sullivan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: